An observational study in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 20 sites in Turkey. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-07-21.
Sponsored by AstraZeneca · Observational
The purpose of this study is to investigate the effects of Chronic Obstructive Pulmonary Disease (COPD) on daily life activities in patients with COPD and also to determine the socio-demographic profile, daily life style and needs of the patients with COPD.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 497 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Outpatients from health institutions where the patients with COPD are treated
Exclusion Criteria:
Effect of COPD on daily activities
The distribution of the patients according to their answers, as Yes / No / Unknown, given to the questions of patient questionnaire about the effect of COPD on daily life and which daily activities are limited will be calculated as percentage.
Time frame: 1 year
Patients' socio-demographic profiles, daily life conditions and needs and expectations from therapy
The answers the patients give to the questions about socio-demographic profiles, daily life conditions and needs and their expectations from the therapy will be summarized as percentages: Age and gender, educational background, place of residence, marital status and life conditions, concomitant diseases, smoking status, the diagnosis of COPD and its clinical characteristics basic knowledge of the patient about COPD daily life of the patient, expectations from the therapy.
Time frame: Baseline
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca